193,752 Shares in TransMedics Group, Inc. $TMDX Purchased by Bank of New York Mellon Corp

Key Points

• Bank of New York Mellon purchased 193,752 TransMedics shares worth approximately $12.9 million, representing about 0.56% of the company. Institutional investors collectively own 99.67% of TMDX.
• Analyst sentiment is mixed, with six Buy, six Hold, and one Sell rating; the consensus rating is Hold with a $124.18 price target.
• TransMedics reported quarterly revenue of $189.95 million, up 20.7% year over year and above estimates, but earnings of $0.44 per share missed the $0.50 consensus. The stock opened at $82.24, down 3.1%.

Bank of New York Mellon Corp purchased a new stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 193,752 shares of the company's stock, valued at approximately $12,869,000. Bank of New York Mellon Corp owned about 0.56% of TransMedics Group as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its holdings in TransMedics Group by 50.1% during the fourth quarter. Goldman Sachs Group Inc. now owns 965,931 shares of the company's stock worth $117,506,000 after buying an additional 322,353 shares during the last quarter. Two Sigma Investments LP increased its stake in shares of TransMedics Group by 54.2% during the 3rd quarter. Two Sigma Investments LP now owns 635,394 shares of the company's stock worth $71,291,000 after purchasing an additional 223,409 shares during the last quarter. Wellington Management Group LLP increased its stake in shares of TransMedics Group by 100.5% during the 4th quarter. Wellington Management Group LLP now owns 433,321 shares of the company's stock worth $52,713,000 after purchasing an additional 217,180 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of TransMedics Group by 43.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 569,970 shares of the company's stock valued at $69,338,000 after purchasing an additional 171,810 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of TransMedics Group by 11.9% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,069,492 shares of the company's stock valued at $119,997,000 after purchasing an additional 113,817 shares during the period. 99.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently commented on TMDX shares. Wall Street Zen cut TransMedics Group from a "hold" rating to a "sell" rating in a report on Saturday, May 9th. TD Cowen reaffirmed a "buy" rating and issued a $120.00 price objective on shares of TransMedics Group in a research report on Wednesday, July 1st. Zacks Research downgraded TransMedics Group from a "hold" rating to a "strong sell" rating in a research note on Monday, July 6th. Oppenheimer lowered TransMedics Group from an "outperform" rating to a "market perform" rating in a report on Wednesday, May 6th. Finally, Stifel Nicolaus increased their price target on TransMedics Group from $75.00 to $80.00 and gave the company a "hold" rating in a research note on Thursday, June 18th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $124.18.

TransMedics Group Trading Down 3.1%

TMDX stock opened at $82.24 on Wednesday. TransMedics Group, Inc. has a 52 week low of $60.10 and a 52 week high of $156.00. The company has a market capitalization of $2.84 billion, a PE ratio of 21.14 and a beta of 1.90. The company's 50-day simple moving average is $79.40 and its 200 day simple moving average is $92.84. The company has a debt-to-equity ratio of 1.62, a quick ratio of 6.07 and a current ratio of 6.62.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The business had revenue of $189.95 million for the quarter, compared to the consensus estimate of $184.00 million. During the same period in the prior year, the business posted $0.92 earnings per share. The firm's revenue for the quarter was up 20.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that TransMedics Group, Inc. will post 1.46 earnings per share for the current year.

Insider Buying and Selling

In other TransMedics Group news, Director Thomas J. Gunderson sold 9,624 shares of TransMedics Group stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares of the company's stock, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is currently owned by company insiders.

TransMedics Group Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company's flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics' solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source